FOOD AND DRUG ADMINISTRATION (FDA) 
Center for Drug Evaluation and Research (CDER) 

 

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting 

Hilton Washington DC North/Gaithersburg, The Grand Ballroom 

620 Perry Parkway, Gaithersburg, MD 20877 

June 10, 2015  

MEETING ROSTER 

 

 
 

DESIGNATED FEDERAL OFFICER (Non-Voting) 
 
Philip A. Bautista, PharmD  
Division of Advisory Committee and Consultant Management 
Office of Executive Programs, CDER, FDA 
 
ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS 
(Voting) 
 
David W. Cooke, MD 
Associate Professor of Pediatrics 
Clinical Director, Division of Pediatric 
Endocrinology 
Director, Pediatric Endocrine Fellowship Training 
Program 
Johns Hopkins University School of Medicine 
Baltimore, Maryland 
  
William R. Hiatt, MD, FACP, FAHA 
Professor of Medicine  
Division of Cardiology 
University of Colorado School of Medicine  
President, Colorado Prevention Center 
Clinical Research 
Aurora, Colorado  
 

Charles A. Stanley, MD 
Professor of Pediatrics 
Perelman School of Medicine University of 
Pennsylvania  
Division of Endocrinology & Diabetes 
Childrenâ€™s Hospital of Philadelphia 
Philadelphia, Pennsylvania 

Peter W. F. Wilson, MD 
Director 
Epidemiology and Genomic Medicine 
Atlanta Veterans Administration Medical Center 
Professor of Medicine and Public Health 
Emory University 
Emory Clinical Cardiovascular Research Institute 
Atlanta, Georgia 
 
 

Robert J. Smith, MD 
(Chairperson) 
Professor of Medicine (Endocrinology) 
Alpert Medical School of Brown University 
Ocean State Research Institute 
Providence Veterans Administration Medical Center
Providence, Rhode Island 
 
 
 
 
 
 
 
 
 

 

Page 1 of 3 

FOOD AND DRUG ADMINISTRATION (FDA) 
Center for Drug Evaluation and Research (CDER) 

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting 

 

 

June 10, 2015  

MEETING ROSTER (cont.) 

 

 

Michele Orza, ScD 
(Acting Consumer Representative) 
Senior Advisor to the Executive Director 
Patient-Centered Outcomes Research Institute 
Washington, District of Columbia 
 

Yves Rosenberg, MD, MPH 
Branch Chief, Atherothrombosis and Coronary 
Artery Disease Branch 
Adult and Pediatric Cardiac Research Program 
Division of Cardiovascular Services 
National Heart, Lung, and Blood Institute (NHLBI) 
National Institutes of Health (NIH) 
Bethesda, Maryland 
 
Philip Sager, MD, FACC, FAHA 
Consulting Professor of Medicine  
Stanford University School of Medicine 
Chair, Scientific Programs Committee 
Cardiac Safety Research Consortium  
San Francisco, California 

Robert D. Shamburek, MD 
Clinician/Scientist 
Lipoprotein Metabolism Section 
Cardiovascular and Pulmonary Branch 
NHLBI, NIH 
Bethesda, Maryland 
 
Abraham Thomas, MD, MPH 
Senior Vice President and Chair 
Department of Medicine 
New York University Lutheran 
Brooklyn, New York 
 

 
TEMPORARY MEMBERS (Voting) 
 
Michael J. Blaha, MD, MPH 
Director of Clinical Research 
Ciccarone Center for Prevention of Heart Disease 
Assistant Professor 
Johns Hopkins University School of Medicine 
Baltimore, Maryland 
 
Daniel Budnitz, MD, MPH 
CAPT, US Public Health Service 
Director, Medication Safety Program 
Division of Healthcare Quality Promotion 
Centers for Disease Control and Prevention 
Atlanta, Georgia 
 

Kenneth D. Burman, MD 
Professor of Medicine 
Georgetown University and Uniformed Services 
University of the Health Sciences 
Director, Section of Endocrinology 
MedStar Washington Hospital Center 
Washington, District of Columbia 
 
Debra G. McCall, MBA 
(Patient Representative) 
Murrieta, California 
 

Martha Nason, PhD 
Mathematical Statistician 
Biostatistics Research Branch, Division of 
Clinical Research 
National Institute of Allergy and Infectious  
Diseases, NIH 
Bethesda, Maryland 
 
 
 
 
 
 

Page 2 of 3 

FOOD AND DRUG ADMINISTRATION (FDA) 
Center for Drug Evaluation and Research (CDER) 

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting 

 

 

June 10, 2015  

MEETING ROSTER (cont.) 

 

 

 

 
ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting) 
 
Helmut H. Albrecht, MD, MS, FFPM 
(Acting Industry Representative) 
Principal, H2A Associates, LLC 
Miami, Florida 
 
FDA PARTICIPANTS (Non-Voting) 
 
Curtis J. Rosebraugh, MD 
Director 
Office of Drug Evaluation II (ODE II) 
Office of New Drugs (OND), CDER, FDA 
 

Jean-Marc Guettier, MD 
Director 
Division of Metabolism and Endocrinology  
Products (DMEP) 
ODE II, OND, CDER, FDA 
 
Eileen Craig, MD 
Medical Officer 
DMEP, ODE II, OND, CDER, FDA 
 
 

James P. Smith, MD, MS 
Deputy Director 
DMEP, ODE II, OND, CDER, FDA 
 
 
 

Page 3 of 3 

